Bedtime-to-Morning Glucose Difference and iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L.

Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
Ariel ZismanVanita R Aroda

Abstract

A difference of ≥ 50-55 mg/dL between bedtime and morning glucose (BeAM) values in patients with type 2 diabetes (T2D) on basal insulin is an indicator of poor postprandial glucose control. This analysis compared the effect of treatment with a fixed-ratio combination of insulin glargine/lixisenatide (iGlarLixi) vs insulin glargine (iGlar) on BeAM values, and evaluated the impact of BeAM values on glycemic and safety endpoints. In this post hoc analysis of 517 participants from the LixiLan-L trial, change in BeAM values and composite efficacy and safety endpoints stratified by BeAM value < 55 mg/dL or ≥ 55 mg/dL were evaluated in patients with T2D uncontrolled on basal insulin randomized to iGlarLixi or iGlar over 30 weeks (LixiLan-L). Greater reductions in BeAM values were seen with iGlarLixi vs iGlar, and a higher proportion of patients reached a BeAM value < 55 mg/dL in the iGlarLixi arm. A BeAM value < 55 mg/dL was associated with improved glycemic control, lower risk of hypoglycemia, and a greater proportion of patients achieving glycemic targets without hypoglycemia or weight gain. Greater reductions in BeAM values were seen with iGlarLixi vs iGlar, irrespective of stratification by glycated hemoglobin A1c or glycemic endp...Continue Reading

References

Oct 12, 2016·Primary Care Diabetes·Kamlesh Khunti, David Millar-Jones
Mar 24, 2018·Postgraduate Medicine·Eric L JohnsonJennifer M Trujillo
Mar 31, 2018·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Lawrence BlondeRory J McCrimmon

❮ Previous
Next ❯

Citations

Jul 24, 2020·Clinical Diabetes : a Publication of the American Diabetes Association·Kevin Cowart

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02058160

Software Mentioned

iGlarLixi
iGlar
LixiLan

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.